|Videos|May 25, 2022
Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5